Chinese Japanese Germany


Hypoglycemic agents Hypoglycemic effect Precautions Chemical properties Uses Hazards & Safety Information
Chemical Name:
hb419;hd419;ur606;adiab;Malix;HB 419;HD 419;u26452;UR 606;Daonil
Molecular Formula:
Formula Weight:
MOL File:

Glibenclamide Properties

Melting point:
1.1805 (rough estimate)
refractive index 
1.6100 (estimate)
storage temp. 
ethanol: soluble2mg/mL
5.3(at 25℃)
White solid
Water Solubility 
Soluble in ethanol (5 mg/mL), DMSO (25 mg/mL), chloroform (1:36), methanol (1:250), and DMF. Insoluble in water.
CAS DataBase Reference
10238-21-8(CAS DataBase Reference)
NIST Chemistry Reference
  • Risk and Safety Statements
  • Hazard and Precautionary Statements (GHS)
Hazard Codes  Xn
Risk Statements  20/21/22
Safety Statements  22-36/37/39-36-24/25
WGK Germany  2
RTECS  YS4725200
HS Code  29350090
Toxicity LD50 in rats and mice (g/kg): >20 orally; >12.5 i.p.; >20 s.c. (Mizukami)
Signal word:
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H303 May be harmfulif swallowed Acute toxicity,oral Category 5 P312
Precautionary statements:

Glibenclamide price More Price(13)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich 356310 Glyburide A sulfonylurea that selectively blocks ATP-sensitive K 10238-21-8 1gm $75.2 2018-11-20 Buy
Sigma-Aldrich 1295505 Glyburide United States Pharmacopeia (USP) Reference Standard 10238-21-8 200mg $348 2018-11-13 Buy
TCI Chemical G0382 Glibenclamide >98.5%(HPLC)(T) 10238-21-8 5g $32 2018-11-22 Buy
TCI Chemical G0382 Glibenclamide >98.5%(HPLC)(T) 10238-21-8 25g $74 2018-11-22 Buy
Alfa Aesar B21459 Glybenzcyclamide, 99% 10238-21-8 100g $284 2018-11-13 Buy

Glibenclamide Chemical Properties,Uses,Production

Hypoglycemic agents

Glibenclamide belongs to the second generation oral sulfonylurea drugs with the mechanism of action being similar as tolbutamide and the hypoglycemic effect being strongest among sulfonylurea drugs. Its intensity of action is about 200 to 250 times of that of Tolbutamide. It can selectively act on the pancreatic β-cells, promote insulin secretion; can enhance the hypoglycemic effect of exogenous insulin and strengthen the post-receptor effect of insulin. It has fast oral absorption with high protein binding rate. It begins to take effect after 30 minutes with the effect being strongest at 1.5 hours and the duration of 16 to 24 hours. It has a distribution volume of 0.1L/kg, plasma protein binding rate of 90% to 95% and half-life of 4 to 8 hours. It is mainly consumed by the liver metabolism with six metabolites. Two of them are known as hydroxylated compounds with no hypoglycemic effect and is mainly excreted from the urine and a small amount is excreted by the stool. It is clinically mainly used for the treatment of mild to moderate non-insulin dependent diabetes mellitus.
Recently, an international study found that the commonly used diabetes drug glibenclamide can help the body's immune system to fight against certain bacterial infections, e.g. in the treatment of melioidosis, the mortality rate can be reduced by about half.
Melioidosis is a disease prevalent in tropical areas such as Southeast Asia and northern Australia. It is caused by Burkholderia pseudomallei with the symptoms including sepsis and pneumonia. The mortality rate is high. Diabetic patients tend to be more susceptible to melioidosis, but the mortality rate is lower compared with other patients.

Hypoglycemic effect

Glibenclamide is currently one of the most commonly used drugs for the treatment of type 2 diabetes. Because this product has fast and strong effect, so the effect after the application remarkable, being able to have good control of blood sugar; being applicable for patients of high blood sugar who get bad efficacy when treated with other sulfonyl Urea hypoglycemic agents.
Two commonly sulfonylurea oral hypoglycemic agents are glibenclamide and glimepiride, the comparison of hypoglycemic effect of them two are as follow:
(1) The effect on glucose transport and metabolism: Glibenclamide and glimepiride can stimulate the key enzymes in the glucose metabolism and improve the glucose transporter (GLUT4) translocation/dephosphorylation to promote the glucose uptake of the surrounding tissue, specifically exhibited in glycogen synthesis and increased fat formation. Glycogen synthase and 3-phosphoglycerol fatty acyltransferase are the key enzymes in glycogen and fat synthesis, and glimepiride is more active than glibenclamide in activating these key enzymes, such as for activating glycogen synthase activity, glimepiride is 2.5 times that of glibenclamide; for the capability to activate lipase, glimepiride is 1.9 times that of glibenclamide. Glimepiride increased the expression of GLUT4 on the cell membrane by inducing dephosphorylation of GLUT4.
 (2) Effect on glycosylated-phosphatidylinositol-specific phospholipase (GPI-PLC): GPI is located in the outer layer of the cell membrane and participates in insulin signal transduction, which can interfere with glucose metabolism of muscle and adipocytes. GPI-PLC can shed the GPI, thereby improving the cell phosphorylation status. Insulin and sulfonylureas can activate GPI-PLC, helping muscle, adipose tissue for the uptake and transport of glucose. However, in the presence of insulin resistance, insulin itself is very difficult to activate GPI-PLC, but glimepiride can still activate the enzyme. In vitro and in vivo studies have shown that, glimepiride has the strongest pancreatic effect in sulfonylurea drugs, which can increase glucose synthesis by 2.5 times and fat synthesis by 4 times. The ratio of glimepiride to glibenclamide was 2: 1. Therefore, glimepiride has a lower secondary failure incidence than other sulfonylurea drugs.


Glibenclamide should be started at low doses. During treatment, it should be regularly checked of the urine sugar, urine ketone body, urine protein and blood sugar, blood routine examination, liver and kidney function, vision, retinal blood vessels.
(1) Patients of liver and kidney dysfunction, leukopenia, sulfa allergy, pregnant women and diabetes complicated by acidosis and acute infection should be disabled.
(2) It can cause abdominal distension, abdominal pain, anorexia, nausea and other gastrointestinal reactions. It can also appear as allergy (skin erythema or urticaria), leukopenia, granulocyte deficiency, thrombocytopenia, hypoglycemia, etc., should be immediately discontinued and treated. Among them, hypoglycemia reaction is more common.
(3) Glibenclamide and other sulfonylurea hypoglycemic agents can’t be combined with thiazide diuretics or glucocorticoids.
(4) It should be avoided to taken together with anticoagulant drugs such as dicoumaroline.
(5) When combined with phenylbutazone, the hypoglycemic effect can be enhanced, causing acute hypoglycemia.
(6) Combination with sulfonamides can enhance both the effect and toxicity of glibenclamide, not suitable for use.
(7) Combination with chloramphenicol can also enhance the effect and toxicity of this product; combination of two drugs demands dose adjustment according to the patient's blood sugar levels, otherwise can cause hypoglycemic shock.
(8) Sulfonylurea drugs can enhance the toxicity of alcohol; alcohol should be avoided during treatment.

Chemical properties

It appears as white crystalline powder. M.p. 168-173 ° C. It is insoluble in water, slightly soluble in ethanol, acetone and chloroform.


Hypoglycemic agents with stronger effect than toluene sulfonylurea; used for the treatment of mild, non-insulin-dependent diabetes;

Hazards & Safety Information

Category : Toxic substances
Toxic classification:  poisoning
Acute toxicity:  Intraperitoneal-rat LD50: 3750 mg/kg; Oral-mouse LD50: 3250 mg/kg
Flammability Hazardous characteristics : Thermal decomposition releases toxic nitrogen oxides, sulfur oxides, chloride fumes
Storage and transport characteristics:  Treasury: low temperature, ventilated and dry
Extinguishing agent : water, carbon dioxide, foam, dry powder

Chemical Properties

White or almost white, crystalline powder




Glyburide is a second generation sulfonylurea with hypoglycemic activity. Glyburide is an antidiabetic.


An ATP-dependent KIR6 and CFTR Cl- channel blocker


ChEBI: An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.

brand name

Micronase (Pharmacia & Upjohn).

Biological Activity

ATP-dependent K + channel (K ATP ) and CFTR Cl - channel blocker. Inhibits K ATP currents in the pancreas, causing an increase in intracellular Ca 2+ and insulin secretion. Inhibits recombinant CFTR Cl- channels with an IC 50 of 20 μ M.

Glibenclamide Preparation Products And Raw materials

Raw materials

Preparation Products

Glibenclamide Suppliers

Global( 288)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 China 19958 60
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 CHINA 3218 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 22059 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 20795 55
Mainchem Co., Ltd.
+86-0592-6210733 CHINA 32764 55
Rixing Chemical CO.,LTD
- CHINA 235 55
Hubei XinRunde Chemical Co., Ltd.
+8615102730682; +8618874586545
02783214688 CHINA 552 55
Jinan Tenglong Chemical Co.,Ltd
Whatsapp:+8615563263311 Skype:live:smions7080 CHINA 778 58
career henan chemical co
+86-371-86658258 CHINA 20001 58
Shanghai Zheyan Biotech Co., Ltd.
18017610038 CHINA 3624 58

View Lastest Price from Glibenclamide manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-03-15 glibenclamide
US $10.00 / KG 10KG 99.5%-101% 10MT Hubei XinRunde Chemical Co., Ltd.
2018-08-20 Glibenclamide
US $1.00 / KG 1G 98% 100KG career henan chemical co

10238-21-8(Glibenclamide)Related Search:

Copyright 2017 © ChemicalBook. All rights reserved